Genvinset® deltaF508 is a semi‑automated in vitro diagnostic kit for the qualitative detection of wild‑type and/or F508del alleles of the CFTR gene, associated with cystic fibrosis. The assay is performed on genomic DNA extracted from whole blood using real‑time PCR with TaqMan® probes.

Detailed description

Key features

Genvinset® deltaF508 is designed for the molecular determination of the F508del mutation, also known as ΔF508, in the CFTR gene. This mutation is associated with cystic fibrosis, an autosomal recessive genetic disease that affects various organs and is related to alterations in water and ion transport across the epithelium.

Principle of operation

The assay is based on real‑time PCR with TaqMan® probes. For each sample, a pair of CFTR gene‑specific primers and two allele‑specific hydrolysis probes are used:

Probe specific for the wild‑type allele labelled with HEX. Probe specific for the F508del allele labelled with FAM.

Interpretation is performed using the FAM and HEX/VIC channels:

Genvinset deltaF508 result interpretation
wt/wt samples: signal in HEX and absence of signal or weak signal in FAM. F508del/F508del samples: signal in FAM and absence of signal or weak signal in HEX. wt/F508del samples: signal in both channels, FAM and HEX.

Clinical applications

This kit is used as an auxiliary tool for the molecular diagnosis of patients with suspected cystic fibrosis. It is intended for patients referred by a healthcare specialist, taking into account compatible symptoms such as pulmonary infections or pneumonia, wheezing, cough with thick mucus, digestive disorders, difficulty gaining weight or growing, very salty sweat and/or a family history of cystic fibrosis.

It can also be used in neonatal patients for the molecular confirmation of cystic fibrosis after observing deviations in biochemical newborn screening, especially in the presence of abnormal immunoreactive trypsinogen values.

Assay results should not be used as the sole criterion for therapeutic decision‑making, but rather as diagnostic support together with other disease markers and the patient’s clinical information.

Benefits

Provides a specific solution for the qualitative detection of wild‑type and mutant alleles for the F508del variant of the CFTR gene using a technology widely used in molecular diagnostics. High diagnostic and analytical reliability. Allows discrimination between wild‑type and mutant alleles in a single reaction, facilitating the identification of the three genotypic profiles covered by the assay. Includes specific controls that ensure standardisation and technical quality checks: wild‑type control, F508del mutant control and Reaction Blank as a negative control. Compatible with most real‑time PCR thermal cyclers commonly used in laboratories.

Considerations or limitations

The product must be used strictly in accordance with the instructions for use. It should not be used if contamination, deterioration, loss of reactivity is suspected, or if the kit has exceeded its expiration date. Genotyping results and their interpretation must be reviewed by qualified personnel.

Key features

CE‑IVD kit for molecular diagnosis of the F508del mutation of the CFTR gene. Qualitative detection of wild‑type and/or F508del alleles associated with cystic fibrosis. Real‑time PCR technology with TaqMan® probes. Differentiation of wt/wt, wt/F508del and F508del/F508del samples using FAM and HEX/VIC channels. Complete kit with included controls, ensuring standardisation and quality control. Compatible with multiple validated real‑time PCR platforms.

Presentation Details

Formats: 24, 48 and 96 tests References: GVS-DF508-24, GVS-DF508-48, GVS-DF508-96
×

Area:

Cystic fibrosis, Molecular Genetics, Targeted study of specific pathologies
Consult our experts

Google reCaptcha: Invalid site key.

Related products

SureSelect Cancer CGP Assay

Targeted-enrichment NGS pan-cancer panel for comprehensive genomic profiling (CGP) of solid tumours. Designed to detect somatic variants at DNA level (SNVs, indels, CNVs, translocations) and RNA level (gene fusions), as well as to assess complex immuno-oncology biomarkers such as tumour mutational burden (TMB), microsatellite instability (MSI) and homologous recombination deficiency (HRD). Detailed Description Operating principle…
Agilent
Next Generation Sequencing (NGS)

SeqOne HRD Solution con Agilent SureSelect CD HRR17 Panel

HRD analysis solution combining low-coverage whole-genome sequencing (shallow/low-pass WGS) and a targeted gene panel to detect genomic instability, BRCA1/2 alterations and other genes related to homologous recombination. It is designed for laboratories wishing to implement HRD testing in-house with an automated, efficient and clinically validated workflow. Detailed Description SeqOne’s HRD solution combines shallow WGS and…
Agilent
Next Generation Sequencing (NGS)

OncoSELECT®

Comprehensive targeted liquid biopsy assay designed to support decision-making in oncology through the analysis of 74 clinically relevant genes. The solution encompasses everything from library preparation reagents to bioinformatics analysis, clinical interpretation and the generation of detailed reports. 3.- Detailed Description Operating principle OncoSELECT® is an advanced liquid biopsy panel based on circulating cell-free DNA…
OncoDNA
Next Generation Sequencing (NGS)

Agilent SureSelect Human All Exon V8.

High-performance exome for the enrichment of human coding regions, with updated coverage of RefSeq, CCDS and GENCODE, including the TERT promoter and difficult-to-capture exons. 3.- Detailed Description Operating principle SureSelect Human All Exon V8 is based on NGS library preparation and capture enrichment of target regions of the human exome. The workflow is compatible with…
Agilent
Next Generation Sequencing (NGS)